Latest Pharma Insights
Altimmune’s 48-Week MASH Data Still Leave Doubts On Fibrosis Benefit
After a disappointing 24-week Phase IIb readout in March, Altimmune presented 48-week data for pemvidutide showing evidence of fibrosis benefit from non-invasive tests, but investors aren't convinced.
Scrip - December 22, 2025
After a disappointing 24-week Phase IIb readout in March, Altimmune presented 48-week data for pemvidutide showing evidence of fibrosis benefit from non-invasive tests, but investors aren't convinced.
Scrip - December 22, 2025
‘Innovating For Our Customers’ Needs’ Is Focus For Philips’ Bert van Meurs
During his 40 years at Royal Philips, Bert van Meurs has seen the medical devices business grow in line with the evolving needs of healthcare providers with whom the company partners in customer and patient focused innovation.
Medtech Insight - December 22, 2025
During his 40 years at Royal Philips, Bert van Meurs has seen the medical devices business grow in line with the evolving needs of healthcare providers with whom the company partners in customer and patient focused innovation.
Medtech Insight - December 22, 2025
UK Perspective: Where 2025 Was About Promise, 2026 Will Be About Execution
A forward-looking view of prospects for regulatory and market access improvement from the UK’s biggest medtech industry lobby group, the Association of British HealthTech Industries (ABHI).
Medtech Insight - December 22, 2025
A forward-looking view of prospects for regulatory and market access improvement from the UK’s biggest medtech industry lobby group, the Association of British HealthTech Industries (ABHI).
Medtech Insight - December 22, 2025
French Finance Bill Expected To Bring Increased Burden For Pharma
The French national assembly has adopted a version of the 2026 social security finance bill that includes price cuts and penalties for companies that adopt tactics to delay generic entry.
Pink Sheet - December 22, 2025
The French national assembly has adopted a version of the 2026 social security finance bill that includes price cuts and penalties for companies that adopt tactics to delay generic entry.
Pink Sheet - December 22, 2025
Alvotech Sees Out 2025 With Simponi Biosimilar Debut In Europe
Alvotech and marketing partner Advanz Pharma have claimed a first with the launch of their Gobivaz golimumab biosimilar rival to Simponi in Europe.
Generics Bulletin - December 22, 2025
Alvotech and marketing partner Advanz Pharma have claimed a first with the launch of their Gobivaz golimumab biosimilar rival to Simponi in Europe.
Generics Bulletin - December 22, 2025
Ipsen Snaps Up Another ADC With Simcere Zaiming Pact
Deal Snapshot: Days after the disappointment of a mid-stage fail for its rare disease fidrisertib, Ipsen has hit the M&A trail to boost its oncology efforts and license an antibody-drug conjugate (ADC) from Simcere Zaiming.
Scrip - December 22, 2025
Deal Snapshot: Days after the disappointment of a mid-stage fail for its rare disease fidrisertib, Ipsen has hit the M&A trail to boost its oncology efforts and license an antibody-drug conjugate (ADC) from Simcere Zaiming.
Scrip - December 22, 2025
Clinical Trial Hits Of 2025
R&D advances are grist to the pharma mill, and those clinical trials that can be deemed successes are particularly welcome. Here are the top five or so study hits (many come in pairs) that got readers clicking in 2025.
Scrip - December 22, 2025
R&D advances are grist to the pharma mill, and those clinical trials that can be deemed successes are particularly welcome. Here are the top five or so study hits (many come in pairs) that got readers clicking in 2025.
Scrip - December 22, 2025
IQVIA Consumer Health: Real World Consumer Surveys Offer Competitive Advantage
When conducted according to a rigorous protocol, incorporating validated questionnaires, and meeting the standards for peer-reviewed publication, real world surveys deliver enhanced value, says IQVIA Consumer Health.
HBW Insight - December 22, 2025
When conducted according to a rigorous protocol, incorporating validated questionnaires, and meeting the standards for peer-reviewed publication, real world surveys deliver enhanced value, says IQVIA Consumer Health.
HBW Insight - December 22, 2025
Nestlé Takes Expanded Materna Supplements Range To China
China will be the first market to see the introduction of Nestlé's expanded pregnancy supplement line, Materna.
HBW Insight - December 22, 2025
China will be the first market to see the introduction of Nestlé's expanded pregnancy supplement line, Materna.
HBW Insight - December 22, 2025
Deloitte Survey Finds AI’s Return On Investment Lags Expectations
Analyst Pete Lyons said lagging returns are part of a maturity curve for new technology.
Scrip - December 22, 2025
Analyst Pete Lyons said lagging returns are part of a maturity curve for new technology.
Scrip - December 22, 2025
Stock Watch: What Biohaven Can Teach Us About Optimism And Reality
Investor optimism can mask real risks; Biohaven’s setbacks show the need for objectivity and caution in pharma investing.
Scrip - December 22, 2025
Investor optimism can mask real risks; Biohaven’s setbacks show the need for objectivity and caution in pharma investing.
Scrip - December 22, 2025
Podcast: “We Are On The Cusp Of A Real Revolution”: OHC Rare Disease Center Boosts Innovation
Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and the challenges around the biopharma industry’s narrow focus on only 5-10% of rare diseases.
In Vivo - December 22, 2025
Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and the challenges around the biopharma industry’s narrow focus on only 5-10% of rare diseases.
In Vivo - December 22, 2025
Topadur Sees Future Expansion From Wound Healing Into Longevity
A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?
In Vivo - December 22, 2025
A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?
In Vivo - December 22, 2025
How MFN And IRP Convergence Are Rewriting Biotech’s Playbook
Biotech’s pricing playbook is being upended as US Most-Favored Nation rules collide with Europe’s evolving International Reference Pricing models. The result: launch strategies, deal structures and innovation pipelines are all under pressure.
In Vivo - December 22, 2025
Biotech’s pricing playbook is being upended as US Most-Favored Nation rules collide with Europe’s evolving International Reference Pricing models. The result: launch strategies, deal structures and innovation pipelines are all under pressure.
In Vivo - December 22, 2025
Cell And Gene Therapy Leaders See Transformative Results Outweighing Industry Setbacks
Executives at the cell and gene therapy accelerator ElevateBio point to clinical impact, expanding toolbox and manufacturing improvements as reasons for optimism.
In Vivo - December 22, 2025
Executives at the cell and gene therapy accelerator ElevateBio point to clinical impact, expanding toolbox and manufacturing improvements as reasons for optimism.
In Vivo - December 22, 2025
AstraZeneca’s Synthetic Lethality Drug Combo Fails In Phase III Trial
AstraZeneca’s attempt to tackle NSCLC drug resistance with ATR inhibition and immunotherapy falls short in the Phase III LATIFY trial.
Scrip - December 22, 2025
AstraZeneca’s attempt to tackle NSCLC drug resistance with ATR inhibition and immunotherapy falls short in the Phase III LATIFY trial.
Scrip - December 22, 2025
‘Anyone Can Be A Buyer’ – Midcaps Gear Up For Pharma M&A Bull Run
A Scrip analysis of cash positions, balance sheets and revenue at risk from patent loss and conference call commentary highlights M&A appetite among large pharma as well as mid-sized players.
Scrip - December 22, 2025
A Scrip analysis of cash positions, balance sheets and revenue at risk from patent loss and conference call commentary highlights M&A appetite among large pharma as well as mid-sized players.
Scrip - December 22, 2025
Pipeline Watch: Three Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - December 22, 2025
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - December 22, 2025
BsUFA IV: Approval Criteria Shift May Mean US FDA User Fee Changes
A Teva official suggested the increasing reliance on analytical characterizations rather than clinical studies to show biosimilarity should warrant user fee structure changes.
Generics Bulletin - December 22, 2025
A Teva official suggested the increasing reliance on analytical characterizations rather than clinical studies to show biosimilarity should warrant user fee structure changes.
Generics Bulletin - December 22, 2025
Biocon Strikes Aflibercept Deal And Launches Liraglutide In Europe
Biocon Biologics has announced a further settlement over Eylea (aflibercept) allowing launch of its Yesafili biosimilar in territories outside of the US and Canada early next year. Meanwhile, Biocon Limited has launched its liraglutide rival to Victoza and Saxenda in the Netherlands.
Generics Bulletin - December 22, 2025
Biocon Biologics has announced a further settlement over Eylea (aflibercept) allowing launch of its Yesafili biosimilar in territories outside of the US and Canada early next year. Meanwhile, Biocon Limited has launched its liraglutide rival to Victoza and Saxenda in the Netherlands.
Generics Bulletin - December 22, 2025
Europe Leads Charge As Private Equity Roars Back Into Off-Patent Pharma
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
Generics Bulletin - December 22, 2025
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
Generics Bulletin - December 22, 2025
GlucoModicum’s Needle-Free Sofio Could Offer Alternative CGM Approach
The system combines a durable rechargeable transmitter with a two-year life span and a replaceable single-day sensor. The product is intended to address pain, inconvenience and adherence challenges associated with multiweek CGM use.
Medtech Insight - December 22, 2025
The system combines a durable rechargeable transmitter with a two-year life span and a replaceable single-day sensor. The product is intended to address pain, inconvenience and adherence challenges associated with multiweek CGM use.
Medtech Insight - December 22, 2025
AstraZeneca Refuels KRAS Push With Jacobio Partnership For Pan-Inhibitor
Deal Snapshot: AstraZeneca will gain global rights to Jacobio’s pan-KRAS inhibitor JAB-23E73 for up to $2bn, after the UK major in November shelved a KRAS G12D inhibitor acquired from Usynova back in 2023.
Scrip - December 22, 2025
Deal Snapshot: AstraZeneca will gain global rights to Jacobio’s pan-KRAS inhibitor JAB-23E73 for up to $2bn, after the UK major in November shelved a KRAS G12D inhibitor acquired from Usynova back in 2023.
Scrip - December 22, 2025
RegCell Looks To Bridge Japan-US Expertise As It Builds Treg Cell Capabilities
The firm founded by Treg cell discoverer Shimon Sakaguchi is building up its US team and refining R&D strategy and manufacturing processes to create an example and global path for other Japanese ventures.
Scrip - December 22, 2025
The firm founded by Treg cell discoverer Shimon Sakaguchi is building up its US team and refining R&D strategy and manufacturing processes to create an example and global path for other Japanese ventures.
Scrip - December 22, 2025
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Regeneron caught between success and expiry; Q3’s top 10 drugs; Lilly’s retatrutide raises weight-loss bar; Pfizer stands by vaccines investment; and Sanofi upbeat despite tolebrutinib tribulations.
Scrip - December 22, 2025
In this week's episode: Regeneron caught between success and expiry; Q3’s top 10 drugs; Lilly’s retatrutide raises weight-loss bar; Pfizer stands by vaccines investment; and Sanofi upbeat despite tolebrutinib tribulations.
Scrip - December 22, 2025
Altimmune’s 48-Week MASH Data Still Leave Doubts On Fibrosis Benefit
After a disappointing 24-week Phase IIb readout in March, Altimmune presented 48-week data for pemvidutide showing evidence of fibrosis benefit from non-invasive tests, but investors aren't convinced.
Scrip - December 22, 2025
After a disappointing 24-week Phase IIb readout in March, Altimmune presented 48-week data for pemvidutide showing evidence of fibrosis benefit from non-invasive tests, but investors aren't convinced.
Scrip - December 22, 2025
Ipsen Snaps Up Another ADC With Simcere Zaiming Pact
Deal Snapshot: Days after the disappointment of a mid-stage fail for its rare disease fidrisertib, Ipsen has hit the M&A trail to boost its oncology efforts and license an antibody-drug conjugate (ADC) from Simcere Zaiming.
Scrip - December 22, 2025
Deal Snapshot: Days after the disappointment of a mid-stage fail for its rare disease fidrisertib, Ipsen has hit the M&A trail to boost its oncology efforts and license an antibody-drug conjugate (ADC) from Simcere Zaiming.
Scrip - December 22, 2025
Clinical Trial Hits Of 2025
R&D advances are grist to the pharma mill, and those clinical trials that can be deemed successes are particularly welcome. Here are the top five or so study hits (many come in pairs) that got readers clicking in 2025.
Scrip - December 22, 2025
R&D advances are grist to the pharma mill, and those clinical trials that can be deemed successes are particularly welcome. Here are the top five or so study hits (many come in pairs) that got readers clicking in 2025.
Scrip - December 22, 2025
Deloitte Survey Finds AI’s Return On Investment Lags Expectations
Analyst Pete Lyons said lagging returns are part of a maturity curve for new technology.
Scrip - December 22, 2025
Analyst Pete Lyons said lagging returns are part of a maturity curve for new technology.
Scrip - December 22, 2025
Stock Watch: What Biohaven Can Teach Us About Optimism And Reality
Investor optimism can mask real risks; Biohaven’s setbacks show the need for objectivity and caution in pharma investing.
Scrip - December 22, 2025
Investor optimism can mask real risks; Biohaven’s setbacks show the need for objectivity and caution in pharma investing.
Scrip - December 22, 2025
AstraZeneca’s Synthetic Lethality Drug Combo Fails In Phase III Trial
AstraZeneca’s attempt to tackle NSCLC drug resistance with ATR inhibition and immunotherapy falls short in the Phase III LATIFY trial.
Scrip - December 22, 2025
AstraZeneca’s attempt to tackle NSCLC drug resistance with ATR inhibition and immunotherapy falls short in the Phase III LATIFY trial.
Scrip - December 22, 2025
‘Anyone Can Be A Buyer’ – Midcaps Gear Up For Pharma M&A Bull Run
A Scrip analysis of cash positions, balance sheets and revenue at risk from patent loss and conference call commentary highlights M&A appetite among large pharma as well as mid-sized players.
Scrip - December 22, 2025
A Scrip analysis of cash positions, balance sheets and revenue at risk from patent loss and conference call commentary highlights M&A appetite among large pharma as well as mid-sized players.
Scrip - December 22, 2025
Pipeline Watch: Three Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - December 22, 2025
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - December 22, 2025
AstraZeneca Refuels KRAS Push With Jacobio Partnership For Pan-Inhibitor
Deal Snapshot: AstraZeneca will gain global rights to Jacobio’s pan-KRAS inhibitor JAB-23E73 for up to $2bn, after the UK major in November shelved a KRAS G12D inhibitor acquired from Usynova back in 2023.
Scrip - December 22, 2025
Deal Snapshot: AstraZeneca will gain global rights to Jacobio’s pan-KRAS inhibitor JAB-23E73 for up to $2bn, after the UK major in November shelved a KRAS G12D inhibitor acquired from Usynova back in 2023.
Scrip - December 22, 2025
RegCell Looks To Bridge Japan-US Expertise As It Builds Treg Cell Capabilities
The firm founded by Treg cell discoverer Shimon Sakaguchi is building up its US team and refining R&D strategy and manufacturing processes to create an example and global path for other Japanese ventures.
Scrip - December 22, 2025
The firm founded by Treg cell discoverer Shimon Sakaguchi is building up its US team and refining R&D strategy and manufacturing processes to create an example and global path for other Japanese ventures.
Scrip - December 22, 2025
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Regeneron caught between success and expiry; Q3’s top 10 drugs; Lilly’s retatrutide raises weight-loss bar; Pfizer stands by vaccines investment; and Sanofi upbeat despite tolebrutinib tribulations.
Scrip - December 22, 2025
In this week's episode: Regeneron caught between success and expiry; Q3’s top 10 drugs; Lilly’s retatrutide raises weight-loss bar; Pfizer stands by vaccines investment; and Sanofi upbeat despite tolebrutinib tribulations.
Scrip - December 22, 2025
‘Innovating For Our Customers’ Needs’ Is Focus For Philips’ Bert van Meurs
During his 40 years at Royal Philips, Bert van Meurs has seen the medical devices business grow in line with the evolving needs of healthcare providers with whom the company partners in customer and patient focused innovation.
Medtech Insight - December 22, 2025
During his 40 years at Royal Philips, Bert van Meurs has seen the medical devices business grow in line with the evolving needs of healthcare providers with whom the company partners in customer and patient focused innovation.
Medtech Insight - December 22, 2025
UK Perspective: Where 2025 Was About Promise, 2026 Will Be About Execution
A forward-looking view of prospects for regulatory and market access improvement from the UK’s biggest medtech industry lobby group, the Association of British HealthTech Industries (ABHI).
Medtech Insight - December 22, 2025
A forward-looking view of prospects for regulatory and market access improvement from the UK’s biggest medtech industry lobby group, the Association of British HealthTech Industries (ABHI).
Medtech Insight - December 22, 2025
French Finance Bill Expected To Bring Increased Burden For Pharma
The French national assembly has adopted a version of the 2026 social security finance bill that includes price cuts and penalties for companies that adopt tactics to delay generic entry.
Pink Sheet - December 22, 2025
The French national assembly has adopted a version of the 2026 social security finance bill that includes price cuts and penalties for companies that adopt tactics to delay generic entry.
Pink Sheet - December 22, 2025
GlucoModicum’s Needle-Free Sofio Could Offer Alternative CGM Approach
The system combines a durable rechargeable transmitter with a two-year life span and a replaceable single-day sensor. The product is intended to address pain, inconvenience and adherence challenges associated with multiweek CGM use.
Medtech Insight - December 22, 2025
The system combines a durable rechargeable transmitter with a two-year life span and a replaceable single-day sensor. The product is intended to address pain, inconvenience and adherence challenges associated with multiweek CGM use.
Medtech Insight - December 22, 2025
IQVIA Consumer Health: Real World Consumer Surveys Offer Competitive Advantage
When conducted according to a rigorous protocol, incorporating validated questionnaires, and meeting the standards for peer-reviewed publication, real world surveys deliver enhanced value, says IQVIA Consumer Health.
HBW Insight - December 22, 2025
When conducted according to a rigorous protocol, incorporating validated questionnaires, and meeting the standards for peer-reviewed publication, real world surveys deliver enhanced value, says IQVIA Consumer Health.
HBW Insight - December 22, 2025
Nestlé Takes Expanded Materna Supplements Range To China
China will be the first market to see the introduction of Nestlé's expanded pregnancy supplement line, Materna.
HBW Insight - December 22, 2025
China will be the first market to see the introduction of Nestlé's expanded pregnancy supplement line, Materna.
HBW Insight - December 22, 2025
Alvotech Sees Out 2025 With Simponi Biosimilar Debut In Europe
Alvotech and marketing partner Advanz Pharma have claimed a first with the launch of their Gobivaz golimumab biosimilar rival to Simponi in Europe.
Generics Bulletin - December 22, 2025
Alvotech and marketing partner Advanz Pharma have claimed a first with the launch of their Gobivaz golimumab biosimilar rival to Simponi in Europe.
Generics Bulletin - December 22, 2025
BsUFA IV: Approval Criteria Shift May Mean US FDA User Fee Changes
A Teva official suggested the increasing reliance on analytical characterizations rather than clinical studies to show biosimilarity should warrant user fee structure changes.
Generics Bulletin - December 22, 2025
A Teva official suggested the increasing reliance on analytical characterizations rather than clinical studies to show biosimilarity should warrant user fee structure changes.
Generics Bulletin - December 22, 2025
Biocon Strikes Aflibercept Deal And Launches Liraglutide In Europe
Biocon Biologics has announced a further settlement over Eylea (aflibercept) allowing launch of its Yesafili biosimilar in territories outside of the US and Canada early next year. Meanwhile, Biocon Limited has launched its liraglutide rival to Victoza and Saxenda in the Netherlands.
Generics Bulletin - December 22, 2025
Biocon Biologics has announced a further settlement over Eylea (aflibercept) allowing launch of its Yesafili biosimilar in territories outside of the US and Canada early next year. Meanwhile, Biocon Limited has launched its liraglutide rival to Victoza and Saxenda in the Netherlands.
Generics Bulletin - December 22, 2025
Europe Leads Charge As Private Equity Roars Back Into Off-Patent Pharma
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
Generics Bulletin - December 22, 2025
A pair of private equity mega-deals dominated the mergers and acquisitions landscape in 2025, but there was still a clear appetite for smaller, strategic takeovers and tuck-ins across the generics, biosimilars, and off-patent medicines field.
Generics Bulletin - December 22, 2025
Podcast: “We Are On The Cusp Of A Real Revolution”: OHC Rare Disease Center Boosts Innovation
Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and the challenges around the biopharma industry’s narrow focus on only 5-10% of rare diseases.
In Vivo - December 22, 2025
Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and the challenges around the biopharma industry’s narrow focus on only 5-10% of rare diseases.
In Vivo - December 22, 2025
Topadur Sees Future Expansion From Wound Healing Into Longevity
A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?
In Vivo - December 22, 2025
A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?
In Vivo - December 22, 2025
How MFN And IRP Convergence Are Rewriting Biotech’s Playbook
Biotech’s pricing playbook is being upended as US Most-Favored Nation rules collide with Europe’s evolving International Reference Pricing models. The result: launch strategies, deal structures and innovation pipelines are all under pressure.
In Vivo - December 22, 2025
Biotech’s pricing playbook is being upended as US Most-Favored Nation rules collide with Europe’s evolving International Reference Pricing models. The result: launch strategies, deal structures and innovation pipelines are all under pressure.
In Vivo - December 22, 2025
Cell And Gene Therapy Leaders See Transformative Results Outweighing Industry Setbacks
Executives at the cell and gene therapy accelerator ElevateBio point to clinical impact, expanding toolbox and manufacturing improvements as reasons for optimism.
In Vivo - December 22, 2025
Executives at the cell and gene therapy accelerator ElevateBio point to clinical impact, expanding toolbox and manufacturing improvements as reasons for optimism.
In Vivo - December 22, 2025